Associations between safety, tolerability, and toxicity and the reporting of health ‐related quality of life in phase III randomized trials in common solid tumors

ConclusionsHRQoL is reported in only two ‐thirds of RCTs that describe collecting such data. Reporting of HRQoL is associated with positive trial outcome and higher journal impact factor, but not associated with overall safety and tolerability of anti‐cancer drugs.

Source: Cancer Medicine - September 3, 2020 Category: Cancer & Oncology Authors: Ramy R. Saleh, Nicholas Meti, Domen Ribnikar, Hadar Goldvaser, Alberto Ocana, Arnoud J. Templeton, Bostjan Seruga, Eitan Amir Tags: ORIGINAL RESEARCH Source Type: research